Researchers at the University of California, Davis have developed an innovative platform for creating genetically encoded fluorescent biosensors capable of 1) assessing the formation of GPCR homo and heterodimers, and 2) determining how dimerization impacts protomer conformation in response to ligands.The UC Davis IPN has developed a suite of ~24 biosensors based on GPCR dimers.Collectively called, dimerLights, these modular biosensors have the ability to identify novel dimeric drug targets and assess the impact of ligands on their conformations.In addition to the ~24 biosensors that UC Davis has already developed, the modular platform in principle can easily be adapted to enable the discovery and evaluation of broader GPCR homo/heterodimers than have been tested so far.

Researchers at the University of California, Davis have developed a therapy that combines bioactive lipids with antiretroviral drugs to accelerate viral suppression and promote gut mucosal repair in HIV treatment.

Researchers at the University of California, Davis have developed a novel hybrid microbial-derived oxylipin and endocannabinoid-like molecule designed to enhance gut and brain health by improving barrier integrity, reducing inflammation, and providing neuroprotection.

Researchers at the University of California, Davis have developed advanced epigenetic methods and systems that detect and assess developmental risks in embryos caused by maternal stress prior to conception.

Researchers at the University of California, Davis have discovered inhibiting the gene Gc improves metabolic health by protecting against obesity and type 2 diabetes without appetite suppression or muscle loss.

Researchers at the University of California, Davis have developed a method for creating annealed microgel scaffolds using polyethylene glycol-vinyl sulfone, offering improved efficiency and shelf life.

Researchers at the University of California, Davis have developed a method and composition that direct the growth of long, coronally oriented blood vessels in tissue grafts to improve vascularization and clinical transplant outcomes.

Researchers at the University of California, Davis have developed a unique non-sacrificial synthetic peptide substrate designed to inhibit plasmin activity and prevent tumor progression and ascites formation in cancers characterized by elevated plasmin levels.